Skip to main content
Fig. 2 | Lipids in Health and Disease

Fig. 2

From: Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics

Fig. 2

Medications targeting at metabolic dysfunction of MASLD. DNL, de novo lipogenesis; FAO, fatty acid β-oxidation; IR, insulin resistance; GLP, glucagon-like peptide; GIP, glucose-dependent insulinotropic peptide; FXR, farnesoid X receptor; FGF, fibroblast growth factor; TG, triglycerides; FFA, free fatty acid; THR, thyroid hormone receptor; PPAR, proliferator-activated receptor

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X